The tuition-free program trained unemployed and under-employed Maryland residents for careers in biotechnology and biomedical ...

In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

The real drug development delay? Bad communication.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...

Psychedelic therapy developer Definium Therapeutics convinced a federal judge in Delaware on Wednesday to dismiss a lawsuit ...

A French drugmaker just bet up to $1.75 billion on a cancer drug that's only been tested on 19 patients — why?

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.